ClinicalTrials.gg

Program

Follicle Stimulating Hormone

Also written as “FSH-GEX™”, “Antioxidants + FSH” and “Follitropin Epsilon”.

Its studies are mostly in Infertility, Female · Infertility · Oligospermia, led by 3 companies.

Furthest: phase 4, since Jan 23, 20136 company-led studies, 1 open or runningNext primary completion: Oct 15, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Glycotope30 open or runningphase 2since Jan 23, 2013May 11, 2011none ahead
IBSA Institut Biochimique20 open or runningphase 3since Jun 9, 2006Jun 9, 2006none ahead
Hamad Medical11 open or runningphase 4since Sep 29, 2026Sep 29, 2026Oct 15, 2027phase 4 · NCT07862725

Also a collaborator on its studies: Glycotope Biotechnology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2006First study: phase 3 study in InfertilityNew to IBSA Institut BiochimiqueIBSA Institut Biochimique · NCT00335725 · 151 enrolled · France, Hungary
  2. May 11, 2011Glycotope’s first study: phase 1 study in Infertility, FemaleNew to GlycotopeGlycotope · NCT01354886 · 19 enrolled · Netherlands
  3. Nov 9, 2011Phase 1 study in Infertility, FemaleGlycotope · NCT01477073 · 57 enrolled · Netherlands
  4. Jan 23, 2013Phase 2 study in InfertilityGlycotope · NCT01794208 · 267 enrolled · Germany, Hungary
  5. Jan 23, 2013Phase 3 study in Oocyte DonationIBSA Institut Biochimique · NCT01785095 · 41 enrolled · Spain
  6. Sep 29, 2026Hamad Medical’s first study: phase 4 study in OligospermiaNew to Hamad MedicalHamad Medical · NCT07862725 · 360 planned · Qatar

Ahead

  1. Oct 15, 2027Primary completion: phase 4 study in OligospermiaHamad Medical · NCT07862725

TargetBeta

FSHR →read by rule
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule

Other programs on FSHR

ProgramCompanyFurthest phaseStudies
follitropin alfaruleMerck KGaA, Darmstadt, Germanyphase 426
follitropin deltaruleFerring Pharmaceuticalsphase 318

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07862725Oligospermia · Qatar4Not yet recruitingHamad MedicalOct 15, 2027360
NCT01794208Infertility · Germany, Hungary2CompletedGlycotopeJul 2013267
NCT01785095Oocyte Donation · Spain3CompletedIBSA Institut BiochimiqueJul 201441
NCT01477073Infertility, Female · Netherlands1CompletedGlycotopeApr 201257
NCT01354886Infertility, Female · Netherlands1CompletedGlycotopeOct 201119
NCT00335725Infertility · France, Hungary3CompletedIBSA Institut BiochimiqueDec 2005151

How it is read

Names in the registry

  • “FSH-GEX™”, 2 entries
  • “Follicle Stimulating Hormone”, 2 entries
  • “Antioxidants + FSH”, 1 entry
  • “Follitropin Epsilon”, 1 entry
  • “FSH (Follicle Stimulating Hormone)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.